331 related articles for article (PubMed ID: 33984528)
1. 5-Lipoxygenase as an emerging target against age-related brain disorders.
Yan M; Zhang S; Li C; Liu Y; Zhao J; Wang Y; Yang Y; Zhang L
Ageing Res Rev; 2021 Aug; 69():101359. PubMed ID: 33984528
[TBL] [Abstract][Full Text] [Related]
2. Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer's Disease mice.
Michael J; Unger MS; Poupardin R; Schernthaner P; Mrowetz H; Attems J; Aigner L
Acta Neuropathol Commun; 2020 Aug; 8(1):129. PubMed ID: 32771067
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-193b-3p alleviates focal cerebral ischemia and reperfusion-induced injury in rats by inhibiting 5-lipoxygenase expression.
Chen Z; Yang J; Zhong J; Luo Y; Du W; Hu C; Xia H; Li Y; Zhang J; Li M; Yang Y; Huang H; Peng Z; Tan X; Wang H
Exp Neurol; 2020 May; 327():113223. PubMed ID: 32032565
[TBL] [Abstract][Full Text] [Related]
4. Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder.
Kumar A; Behl T; Jamwal S; Kaur I; Sood A; Kumar P
Mol Biol Rep; 2020 Dec; 47(12):9895-9912. PubMed ID: 33263931
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease.
Rahman SO; Singh RK; Hussain S; Akhtar M; Najmi AK
Eur J Pharmacol; 2019 Jan; 842():208-220. PubMed ID: 30389631
[TBL] [Abstract][Full Text] [Related]
6. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease.
Chen F; Ghosh A; Lin J; Zhang C; Pan Y; Thakur A; Singh K; Hong H; Tang S
Brain Behav Immun; 2020 Aug; 88():844-855. PubMed ID: 32222525
[TBL] [Abstract][Full Text] [Related]
7. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats.
Chu LS; Fang SH; Zhou Y; Yu GL; Wang ML; Zhang WP; Wei EQ
Acta Pharmacol Sin; 2007 Jun; 28(6):763-72. PubMed ID: 17506934
[TBL] [Abstract][Full Text] [Related]
8. 5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.
Sinha S; Doble M; Manju SL
Bioorg Med Chem; 2019 Sep; 27(17):3745-3759. PubMed ID: 31331653
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.
Manev H; Chen H; Dzitoyeva S; Manev R
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):315-9. PubMed ID: 20691748
[TBL] [Abstract][Full Text] [Related]
10. Activation of 5-lipoxygenase after oxygen-glucose deprivation is partly mediated via NMDA receptor in rat cortical neurons.
Ge QF; Wei EQ; Zhang WP; Hu X; Huang XJ; Zhang L; Song Y; Ma ZQ; Chen Z; Luo JH
J Neurochem; 2006 May; 97(4):992-1004. PubMed ID: 16606359
[TBL] [Abstract][Full Text] [Related]
11. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
[TBL] [Abstract][Full Text] [Related]
12. 5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease.
Manev H
Med Hypotheses; 2000 Jan; 54(1):75-6. PubMed ID: 10790729
[TBL] [Abstract][Full Text] [Related]
13. [Research progress in drugs targeting 5-lipoxygenase for age-related diseases].
Li ZJ; Ma YH; Hou XX; Yao TL; Qin XY
Sheng Li Xue Bao; 2023 Dec; 75(6):864-876. PubMed ID: 38151349
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity.
Klegeris A; McGeer PL
Neurobiol Aging; 2002; 23(5):787-94. PubMed ID: 12392782
[TBL] [Abstract][Full Text] [Related]
15. New anti-inflammatory treatment strategy in Alzheimer's disease.
Sugaya K; Uz T; Kumar V; Manev H
Jpn J Pharmacol; 2000 Feb; 82(2):85-94. PubMed ID: 10877525
[TBL] [Abstract][Full Text] [Related]
16. Modulation of neuroinflammation by cysteinyl leukotriene 1 and 2 receptors: implications for cerebral ischemia and neurodegenerative diseases.
Wang Y; Yang Y; Zhang S; Li C; Zhang L
Neurobiol Aging; 2020 Mar; 87():1-10. PubMed ID: 31986345
[TBL] [Abstract][Full Text] [Related]
17. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis.
Kowal-Bielecka O; Distler O; Neidhart M; Künzler P; Rethage J; Nawrath M; Carossino A; Pap T; Müller-Ladner U; Michel BA; Sierakowski S; Matucci-Cerinic M; Gay RE; Gay S
Arthritis Rheum; 2001 Aug; 44(8):1865-75. PubMed ID: 11508440
[TBL] [Abstract][Full Text] [Related]
18. Dual acting anti-inflammatory drugs.
Leone S; Ottani A; Bertolini A
Curr Top Med Chem; 2007; 7(3):265-75. PubMed ID: 17305569
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the enzymes in the leukotriene and prostaglandin pathways in inflammation by 3-aryl isocoumarins.
Ramanan M; Sinha S; Sudarshan K; Aidhen IS; Doble M
Eur J Med Chem; 2016 Nov; 124():428-434. PubMed ID: 27597418
[TBL] [Abstract][Full Text] [Related]
20. Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1.
Zhang XY; Chen L; Yang Y; Xu DM; Zhang SR; Li CT; Zheng W; Yu SY; Wei EQ; Zhang LH
Brain Res; 2014 Jul; 1572():59-71. PubMed ID: 24858057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
